OSLO--(EON: Enhanced Online News)--Serodus ASA (Oslo Axess: SER), a fast-growing Norwegian cardiovascular biopharma company, today announced that the company’s first clinical phase IIa study with SER100 in patients suffering from Isolated Systolic Hypertension has been initiated. The first patient has been enrolled in the study, and the company plans to enroll a total of thirty patients over the next few months. Thus, the clinical study is on schedule and Serodus expects that the last patient will be dosed in the end of the first quarter of 2014.
The participating hospitals are Oslo University Hospital (NO), Medi3 Innlandet (NO), Turku University Hospital (FI), Valkeakoski District Hospital (FI), Brighton and Sussex University Hospital (UK) and Semmelweis University Hospital (HUN).
About Isolated Systolic Hypertension
Isolated Systolic Hypertension (ISH), first described in 1960, is the dominating hypertensive disease in elderly people. This form of hypertension is often difficult to control. The higher the systolic pressure, the higher are the risks of stroke and other cardiovascular adverse events. Therapy resistant ISH is found in many of the patients who at the same time develop drug-induced side effects, which in itself further worsen the risk of cardiovascular events. New therapeutic approaches to effective and safe treatment of ISH are therefore needed. The present clinical phase IIa study aims to document that SER100 –a new compound with a first-in-class mode of action – is safe and can provide a selective reduction of systolic blood pressure in elderly, treatment-resistant ISH patients.
Eva Steiness, Chief Executive Officer of Serodus ASA, commented: “We are looking forward to perform this clinical study in a patient population that is normally difficult to treat. A successful outcome with respect to safety, tolerability and with an effect on an elevated systolic blood pressure in spite of active antihypertensive treatment will be a great step forward in the search for better and more efficacious treatment of those patients who are highly exposed to debilitating complications such as stroke.